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ABSTRACT
Background: Measles vaccination is associated with major reductions in child mortality and
morbidity. In Guinea-Bissau, to limit vaccine wastage, children are only measles-vaccinated if
at least six children aged 9–11 months are present at a vaccination session.
Objective: To estimate the incremental cost-effectiveness of providing measles vaccine (MV)
to all children regardless of age and number of children present.
Methods: We estimated MV coverage among children living in villages cluster-randomized to
MV for all children and among children cluster-randomized to the current restrictive MV
policy (status quo). Prices of MV and injection equipment were obtained from the United
Nations Children’s Fund (UNICEF). Cost savings of hospital admissions averted were collected
from a sample of health facilities. The non-specific mortality effects of MV were estimated and
presented as deaths averted and life years gained (LYG) from providing MV-for-all.
Results: MV coverage at 36 months was 97% in MV-for-all clusters and 84% in restrictive MV
policy clusters. Conservatively assuming 90%wastage of MV under the MV-for-all policy and 40%
under the restrictive MV policy, cost per child vaccinated was USD 3.08 and USD 1.19, respec-
tively. The incremental costs per LYG and death averted of the MV-for-all policy were USD 5.61
and USD 148, respectively. The MV-for-all policy became cost-saving at 88% wastage.
Conclusions: Taking the low cost of MV and the beneficial non-specific effects of MV into
consideration, a 10-dose MV vial should be reclassified as a ‘1+ dose vial’. The vial should be
opened for a single child, irrespective of age, but can vaccinate up to 10 children.
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Background
Since the introduction of measles vaccine (MV) in the
routine vaccination programme inGuinea-Bissau in the
early 1980s, measles-related mortality and morbidity
have decreased markedly [1]. The effectiveness of MV
in preventing measles infection and measles sequelae
has been well documented; in children older than nine
months of age, at least 85% of those vaccinated are
protected against measles after the first dose [2,3].
Measles is however still the leading cause of vaccine-
preventable deaths in children and the fifth leading
cause of death in children under five years of age,
which makes adequate measles control imperative in
the effort to lower child mortality [4].
The cost-effectiveness of MV has been assessed in
several studies; in a systematic review of cost-effective-
ness of vaccines in low- and middle-income countries,
MV was associated with cost-effectiveness ratios of
between USD 1.5 and USD 240 per Disability Adjusted
Life Year (DALY) averted [5]. In a study from Benin, the
cost-effectiveness of routine MV was USD 1.60 per
DALY averted [6]. The average cost-effectiveness of
increasing coverage of MV to 80–95% across countries
in sub-Saharan Africa (World Health Organization
[WHO]Afr-E region) was estimated to be approximately
25 international USD per DALY averted [7]. Although
MV is already deemed highly cost-effective in these
studies, benefits may be underestimated. MV reduces
all-cause morbidity and mortality much more than can
be explained by measles protection alone [8–11]. In a
recent WHO-commissioned review of these so-called
‘non-specific effects’ of MV in low-income countries,
the vaccine was associated with reductions in all-cause
child mortality of up to 46% (95% confidence interval
[CI]: 35–55%) [12].
In Guinea-Bissau in West Africa, routine vaccina-
tions are provided free of charge at health centres and
through outreach services. Nonetheless, MV coverage
rates of the first dose of MV in Guinea-Bissau are sub-
optimal with an estimated coverage of 69% in 2014 [13].
Thus, one-third of children older than 12 months have
not received MV. TheWHO/UNICEF (United Nations
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Children’s Fund) Joint Reporting Form instructs the
Ministry of Health to report vaccination coverage
among infants only. Hence, vaccination of children
older than 12 months does not count in the assessment
of coverage, which is calculated as the number of doses
administered to children < 12 months divided by the
estimated target population. Consequently, although
the WHO recommends that MV should not be limited
to children aged 9–11 months [2], vaccinating children
older than 12 months of age in Guinea-Bissau is con-
sidered wastage. Furthermore, the lyophilized, live MV
comes in 10-dose vials, which has to be used within 6
hours after dilution. Increased focus on wastage of
vaccine doses has made it more difficult to obtain
vaccination. While the MV target wastage rate was
15% in 2010, it was 11% in 2014 [14]. Thus, to meet
the target wastage rate of 11%, a local policy has been
implemented where MV vials are only opened if six or
more children 9–11 months of age are present at the
same time (‘restrictive MV policy’). These very low
wastage targets have also been specified in other
African countries [15], indicating that restrictions on
vial opening may exist in several other countries. In
rural Guinea-Bissau, this restrictive MV policy has
resulted in several missed measles vaccination opportu-
nities and an increased cost burden to households [16].
Taking the non-specific effects of MV into account,
we aimed to assess the incremental cost-effectiveness of
an MV-for-all policy where children are measles-vacci-
nated regardless of age and number of children present,
compared with the current restrictive MV policy (sta-
tus quo).
Methods
Setting
The Bandim Health Project (BHP) has conducted
research based on a routine demographic surveillance
system in Guinea-Bissau since 1978. The BHP follows
182 clusters of approximately 100 women of fertile age
and their children under five years of age in the nine rural
health regions of Guinea-Bissau. The clusters were initi-
ally selected using the methodology used by the
Expanded Programme on Immunization (EPI) for
immunization surveys. Every six months, the clusters
are visited by BHP mobile teams for registration of new
pregnancies and children. The BHP collects information
aimed at assessing the health of all children below five
years of age. At every visit, information on vaccinations is
obtained by inspecting the child’s health card and the date
of the vaccination is noted. A BHP nurse accompanies
the mobile teams and offers routine vaccines to children
who aremissing vaccinations. At all visits, the caretaker is
interviewed about hospital admissions. If the child has
been admitted to hospital since the last visit, a short
questionnaire with information on hospital admission
date, location and duration is completed.
We used costs and effect estimates derived from
studies and registers from the BHP as well as public
sources, described in further detail in what follows.
Costs were estimated from a societal perspective.
The MVEPI study
In February 2011, BHP initiated a cluster-randomized
trial aimed at evaluating the current ‘restrictive MV
policy’, the MVEPI study. The trial studied the effect
on mortality, morbidity and growth of providing MV
for all children regardless of age and number of children
present. The reporting of the results of the trial is forth-
coming. All 182 rural clusters under survey by BHP were
assigned a number, and using STATA to generate ran-
dom numbers, all clusters were randomized to either
‘MV-for-all’ or ‘restrictiveMV policy’. During the biann-
ual visits by the BHP mobile teams, measles-unvacci-
nated children between 9–36 months of age were
eligible for enrolment. Measles-unvaccinated children
in the restrictive MV policy clusters were vaccinated by
the BHP if they were aged 9–11 months at the visit and if
six or more measles-unvaccinated children aged
9–11 months were present at the same time. In the
MV-for-all clusters, all measles-unvaccinated children
aged 9–36 months were measles-vaccinated by the BHP
regardless of number of children present. Throughout
theMVEPI study there were no reported cases ofmeasles
in Guinea-Bissau [17].
Study population
We estimated costs and effects for the 2011 national
birth cohort in Guinea-Bissau, comprising 59,062 chil-
dren [14]. Using the distribution of deaths from the
2011 rural birth cohort under BHP routine surveillance,
we calculated the percentage of children who died
between 0–9 months of age and estimated the number
of children alive to receive MV at 9 months in the
national birth cohort (Table 1).
We derived MV coverage from the 2011 BHP birth
cohort. MV coverage rates at 12, 24 and 36 months were
determined from children with a seen health card
between 12–23 months, 24–35 months and
36–47 months of age, respectively. We used the coverage
in the restrictive MV policy clusters as a proxy for cover-
age under the current restrictive MV policy and MV
coverage in the MV-for-all clusters as a proxy for cover-
age under anMV-for-all policy in the 2011 national birth
cohort.
Costs incurred by the health system
We assumed that the only MV-related costs that would
differ between the two policies were the costs of extra
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vaccine vials, syringes and safety boxes. Thus, we
assumed that health centre staff would not spend extra
time on vaccination in the MV-for-all clusters com-
pared with the restrictive MV policy clusters, as staff
also spend time telling mothers to come back another
day under the restrictive MV policy. The cold chain
equipment has recently been upgraded in Guinea-
Bissau so that all primary health care centres have
solar fridges with space for extra vaccines. We therefore
assumed that it was not necessary to acquire extra cold
chain equipment to provide MV for all.
For calculating the number of vials used under the
current restrictive MV policy, we assumed that 6
children were vaccinated per 10-dose vial, equalling
40% wastage. Under the MV-for-all policy, as a
worst-case scenario, we assumed one vial per child
vaccinated (90% wastage). We also calculated the
median number of children vaccinated per MV vial
in the MV-for-all clusters.
We used the 2015 UNICEF price for a 10-dose
measles vial of 2.65 USD [22]. The price of one
0.5 ml syringe used for administering MV was USD
0.05 and a 5 litre safety box was USD 0.54 [23]. The
price of a 5 ml syringe used for diluting the vaccine
was USD 0.04 [24]. We assumed one 0.5 ml syringe
per child vaccinated, one safety box per 100 children
vaccinated and one 5 ml syringe per MV vial used.
We assumed 5% wastage of syringes.
Hospital admissions
We estimated the hospital admission rates per 1000
person years for children under surveillance by the
BHP, aged 9–48 months born in 2011, based on mater-
nal reports of hospital admissions. The estimates were
calculated separately for children residing in the restric-
tive MV policy clusters and in the MV-for-all clusters.
We applied the hospital admission rates to the
number of person years in the 2011 national birth
cohort. We assessed the mean number of bed days
among children 9–48 months of age who were
admitted to hospital and under survey by the BHP.
The costs of a hospital bed day were estimated to be
USD 14.97 in 2013 [18]. We calculated the costs
saved from averted hospital admissions due to higher
MV coverage in the MV-for-all scenario, by multi-
plying the difference in hospital admissions between
the two policies by the mean admission duration and
by the costs of a hospital bed day. The exact duration
of the non-specific effects of MV is unknown. Thus,
future costs of hospital admissions averted beyond
48 months of age were not taken into account.
Costs incurred by families
The value of the mother’s time spent on accompany-
ing her child to hospital was determined according to
the average earnings across all sectors in the econ-
omy. Based on data on yearly earnings from 36
countries, Knight et al. constructed a regression
model with Gross National Income (GNI) per capita
as the independent variable [19]. For Guinea-Bissau
this model estimated average monthly earnings as 61
USD in 2011 [19]. We converted this to USD 2.8 per
day, assuming 22 working days per month. We multi-
plied the value of the mothers’ time by the mean
duration of bed days per hospital admission and by
the number of admissions averted due to higher MV
coverage.
In a previous study from rural Guinea-Bissau,
mothers on average took their children for MV 1.4
times before succeeding in getting the child vacci-
nated under the current restrictive MV policy [16].
Thus, we added these costs incurred by mothers of
taking their children 0.4 times (USD 0.53) more for
MV to the costs of MV vaccination in the restrictive
MV policy scenario.
Effect
The effect measures were deaths averted and life years
gained (LYG). We calculated deaths averted in four age
Table 1. Model parameters.
Variable used Value Source of information [reference]
2011 birth cohort (number of children) 59,062 [14]
Percentage of the 2011 birth cohort under surveillance by BHP who died before
9 months of age
7.6% BHP surveillance data
2011 birth cohort surviving until 9 months of age (number of children) 54,573
Hospital admission rate among children aged 9–48 months per 1000 person years
(restrictive MV clusters)
12.5 BHP routine surveillance data
Hospital admission rate among children aged 9–48 months per 1000 person years
(MV-for-all clusters)
8.9 BHP routine surveillance data
Mean duration of hospital admission (days) 7.6 BHP routine surveillance data
Cost per hospital bed-day (USD) 14.97 [18]
MV-associated mortality reduction 46% [12]
Household costs of accompanying a child to hospital per day (USD) 2.8 [19]
Life expectancy in Guinea-Bissau (years) 55 [20]
Infant mortality rate (not including neonates) in Guinea-Bissau 47.6/1000 [21]
Mortality rate 1–4 years in Guinea-Bissau 71.2/1000 (17.8 per year) [21]
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groups (9–11 months; 12–23 months; 24–35 months;
36–47 months) using the MV coverage rates at 12, 24
and 36 months, the 2013 post-neonatal infant mortality
rate of 47.6 deaths/1000 live births and 71.2 deaths/
1000 live births in children aged 1–4 years (17.8/1000
live births per year) [21]. We assumed that mortality
was 46% (95% CI: 35–55%) lower in children who were
vaccinated under the MV-for-all policy compared with
MV-unvaccinated children [12]. Incremental LYG
were calculated by multiplying deaths averted with
the standard life expectancy of 55 years [20]. We dis-
counted future life years by 3% per year as recom-
mended by the WHO [25].
Sensitivity analyses
On the cost side, we conducted sensitivity analyses by
assuming that two (80% wastage) and three (70%
wastage) children were vaccinated per vial under the
MV-for-all policy. We also assessed at which wastage
level the MV-for-all policy became cost-saving. On the
effect side, we did sensitivity analyses using a 33%
reduction in mortality, which is the effect of MV seen
in a large randomized controlled trial from Guinea-
Bissau [11]. We also conducted sensitivity analyses
using the 35% and 55% boundaries of the confidence
interval of the all-cause mortality reduction in the
Strategic Advisory Group of Experts on Immunization
(SAGE) analysis (46% (35–55%)) [12]. To inform
potential decision-makers, we also conducted a sensi-
tivity analysis using only costs incurred by the health
system.
Analyses were conducted in STATA version 12.1
(StataCorp, College Station, TX) and Microsoft Excel
(Microsoft Corp, Redmond, WA).
Results
In the 2011 birth cohort under surveillance by BHP,
7.6% of children had died before 9months of age. Of the
children born in 2011, under surveillance by the BHP,
1871 children lived in the restrictive MV clusters and
1978 in the MV-for-all clusters, at the ages of
12–23 months. Seventy-four percent (2862/3849) had
their vaccination card inspected between 12 and
23 months of age, 69% (2599/3794) between 24 and
35 months and 62% (2242/3604) between 36 and
48 months. In the MV-for-all clusters, the BHP team
vaccinated a median of three children perMV vial used.
MV coverage by 3 years of age among children living in
the restrictive MV clusters was 84% whereas it was 97%
among children living in the MV-for-all clusters
(Table 2). Coverage was higher in the MV-for-all clus-
ters at all ages compared with the restrictive MV policy
clusters (Table 3). The hospital admission rate in the
restrictive MV clusters was 12.5 admissions per 1000
person years. For children in theMV-for-all clusters the
hospital admission rate was 8.9 admissions per 1000
person years, 29% (−1–50%) lower than in the restric-
tive-MV policy clusters (p = 0.06). The mean duration
of hospital admissions was 7.6 days (SD 8.0).
Costs incurred by the health system
Under the current restrictiveMV policy, the total costs of
MV amounted to USD 25,497 and the attained coverage
was 84% at 36 months of age. Under the MV-for-all
policy, costs of MV amounted to USD 162,578 to obtain
a coverage of 97% at 36 months of age (Table 2). We
estimated that 54,573 children were alive at 9 months of
age in the 2011 national birth cohort. Among these
children, 626 hospital admissions could be averted
under the MV-for-all policy due to higher MV coverage,
resulting in a saving of USD 71,165 for the health system.
Costs incurred by households
When extra trips to the health centre to obtain MV
incurred by the household was added to the current
restrictive MV policy, the costs of the policy increased
to USD 54,420 (Table 3). Adding the value of mother’s
time spent accompanying her child to hospital,
increased the total cost-saving to USD 84,475 due to
averted hospital admissions (Table 2).
Mortality effects
Assuming a 46% mortality reduction due to higher MV
coverage, 160 deaths could be averted under theMV-for-
all policy compared with the restrictive MV policy
Table 2. Measles vaccine-related costs under the restrictive MV policy and the MV-for-all policy.
Restrictive MV policy MV-for-all policy
Vaccine wastage (Vaccine wastage factor [VWF]) 40% (VWF = 1.67) 90% (VWF = 10)
MV coverage 84% 97%
MV vial costs (USD) 22,676 157,113
Injection supply costs (USD) 2820 5464
Total vaccine costs (USD) 25,497 162,578
Extra household costs of seeking MV (USD) 28,924
Total costs of the policy (USD) 54,420 162,578
Costs per child vaccinated (USD) 1.19 3.08
Cost-savings due to hospital admissions averted (USD) 84,475
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(Table 3). The incremental LYG under the MV-for-all
policy compared with the restrictive MV policy
amounted to 8361 LYG, and 4223 discounted LYG.
Cost-effectiveness
Subtracting the savings of hospital admissions averted,
the costs of the MV-for-all policy were USD 78,102
(Table 4). The policy was highly cost-effective with an
incremental cost-effectiveness ratio of USD 5.61/dis-
counted LYG and USD 148/death averted (Table 4).
Sensitivity analyses
Assuming 80% and 70% wastage, that is, two or three
children vaccinated per 10-dose vial, the MV-for-all
policy was cost-saving compared with the restrictive
MV policy (Table 5). The MV-for-all policy became
cost-saving at a wastage level of 88%.
Assuming a 33% mortality reduction of MV, 115
deaths were averted, the incremental costs per death
averted were USD 206 and the costs per discounted
LYG were USD 7.8. Assuming 90% wastage and the
lower boundary of the confidence interval (35% reduc-
tion in mortality), cost-effectiveness was USD 7.4/LYG
and USD 194/death averted. Using the upper boundary
(55%), cost-effectiveness was USD 4.7/LYG and USD
124/death averted.
Including only costs incurred by the health system,
the incremental cost-effectiveness of an MV-for-all
policy was 15.6 USD/LYG and 412 USD/death averted.
At 83% wastage, MV-for-all was cost-saving when
only taking the costs incurred by the health system
into account.
Discussion
MV coverage was significantly lower in the restrictive
MV clusters (84%) compared with MV-for-all clusters
(97%). The hospital admission rate among children aged
9–48 months in the MV-for-all clusters was 29% lower
than for children in the restrictive MV clusters, in line
with previous findings [26]. The incremental cost-effec-
tiveness ratio of providing MV to all children compared
with the status quo was low (USD 5.61/LYG). For our
base-case analysis, we used a worst-case scenario
assumption of 90% vaccinewastage (one child vaccinated
per vial) under the MV-for-all policy. MV-for-all was
cost-saving at 88% wastage and at 83% if only costs
incurred by the health system were taken into account.
Among children included in theMVEPI study, a median
of three childrenwere vaccinated perMV vial in theMV-
for-all clusters, giving a wastage rate of 70%.
Strengths and limitations
The use of primary data is a major strength of this study.
We estimated MV coverage under two measles vaccina-
tion scenarios using data from a large cluster-rando-
mized trial. Furthermore, all costs were derived from
Guinea-Bissau, making the estimates relevant to the set-
ting. Our hospital admission costs were derived from a
detailed micro-costing study recently conducted in
Guinea-Bissau, from a government perspective [18].
Our study adds important new knowledge since it
assesses the cost-effectiveness of a measles vaccination
policy taking non-specific effects into account. By asses-
sing the effect of MV on all-cause mortality and not
merely on measles infection, we believe that our study
provides ameasure of the true effect of MV, which is also
relevant to settings where measles infection is controlled.
It should be noted that there were no reported cases of
measles during the study period (2011–2015). We used
the meta-estimate derived from a recent WHO review of
non-specific effects as the effect estimate [12]. This
review comprises all studies of the non-specific effects
of MV on child health until 2014, and includes studies
conducted in a range of different settings and
Table 3. Years of life gained by age of measles vaccination.
Age group
Children alive in the
2011 birth cohort
Mortality rate (per
1000 live born)
Coverage
(restrictive MV
clusters)
Coverage (MV-
for-all clusters)
Deaths
averted*
Life years
gained
Discounted life
years gained
9–12 months 54,573 0.0130 67% 75% 26 1480 697
12–23 months 53,891 0.0178 67% 75% 35 1871 937
24–35 months 52,967 0.0178 83% 93% 43 2255 1142
36–48 months 52,067 0.0178 84% 97% 56 2827 1447
Total 84% 97% 160 8361 4223
Note: *Calculation for deaths averted: number of children*mortality rate*0.46*coverage difference.
Table 4. Cost-effectiveness results.
Costs (USD) Incremental effects Incremental cost-effectiveness
Restrictive MV policy 54,420 0 0
MV-for-all policy 78,102 4223 discounted LYG 5.61 USD/LYG
MV-for-all policy 78,102 160 deaths averted 148 USD/death averted
Note: LYG – life years gained.
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populations. We therefore believe that the estimate more
or less reflects the true effect of MV on child health.
Some limitations must be considered. We achieved
a 97% coverage in the MV-for-all clusters using the
BHP infrastructure, thus a similar coverage could
only be achieved in Guinea-Bissau if outreach is
provided to the same extent as the BHP provide
(two household visits per year). Nonetheless, the
restrictive clusters received the same amount of out-
reach, the only differences being the vial opening and
the age restriction on MV. Furthermore, a wastage
rate of 90% in the MV-for-all clusters is a worst-case
scenario – among the children included in the
MVEPI study, a median of three children were vacci-
nated per vial in the MV-for-all clusters. Thus, a
wastage rate of 70% under the MV-for-all scenario
is probably more realistic. Although we included the
value of a household’s time when accompanying a
child for hospital admission and extra costs of taking
a child for MV under the restrictive MV policy, direct
household costs were not included. For instance, we
did not have information on informal payments
made directly to the nurses for vaccinating a child
at the health centre and medical expenses paid out-
of-pocket by the household. Adding out-of-pocket
medical expenses would increase the cost of hospital
admissions, making the MV-for-all policy even more
cost-effective. We did not make assumptions about
hospital admissions or deaths averted beyond four
years of age, although there are studies indicating
that the non-specific effects of MV may last longer
[27]. Mortality effects of non-specific herd immunity
due to increased coverage of MV and lower infectious
pressure were also not taken into account.
Although we have assessed the cost-effectiveness of
MV using a wide variety of costs and effectiveness mea-
sures, preventing illness and death is associated with
more far-reaching benefits. Healthy adults have higher
labour productivity, which may boost economic devel-
opment [28]. Vaccines may also increase school atten-
dance and educational attainment, and contribute to
declines in the fertility rate following improved child
survival [28–30]. Thus, MV is probably much more
cost-effective due to the wider effects of improved child
health and survival than is captured in the present study.
Consistency with other studies
Several studies have assessed the cost-effectiveness of
MV. In a study from the WHO identifying the most
cost-effective child health interventions in sub-Saharan
Africa, increasingMV coverage was highly cost-effective.
Thus, international USD 29/DALY were averted in a
scenario with 80% coverage and international USD 58/
DALY were averted in a scenario with 95% coverage [7].
However, many studies assessing the cost-effectiveness of
routine MV were conducted in connection with the
introduction of MV in the mid-1980s in low-income
countries [31]. Due to declines in measles mortality, the
cost-effectiveness estimates in the older studies no longer
seem relevant for the present setting. Furthermore, we
assessed the non-specific effects of MV on all-cause
mortality. According to the current evidence of non-
specific effects of MV, the main effect of MV on child
survival is due to the non-specific effects [32]. Thus, cost-
effectiveness studies that only include the effect of
measles infection may underestimate the true effect of
MV, making the results of our study difficult to compare
Table 5. Sensitivity analyses.
Costs (USD) Incremental effects Incremental cost-effectiveness
80% MV wastage
Restrictive MV policy 54,420 0 Reference
MV-for-all policy −1779 4223 discounted LYG Cost-saving
MV-for-all policy −1779 160 deaths averted Cost-saving
70% MV wastage
Restrictive MV policy 54,420 0 Reference
MV-for-all policy −28,406 4223 discounted LYG Cost-saving
MV-for-all policy −28,406 160 deaths averted Cost-saving
33% reduction in mortality due
to MV as obtained from trial [11]
Restrictive MV policy 54,420 0 Reference
MV-for-all policy 78,102 3029 discounted LYG 7.8 USD/LYG
MV-for-all policy 78,102 115 deaths averted 206 USD/death averted
Lower confidence interval boundary
from WHO review (35%) [12]
Restrictive MV policy 54,420 0 Reference
MV-for-all policy 78,102 3212 discounted LYG 7.4 USD/LYG
MV-for-all policy 78,102 122 deaths averted 194 USD/death averted
Upper confidence interval boundary
from WHO review (55%) [12]
Restrictive MV policy 43,506 0 Reference
MV-for-all policy 78,102 5050 discounted LYG 4.7 USD/LYG
MV-for-all policy 78,102 192 deaths averted 124 USD/death averted
Using only costs incurred by the health system
Restrictive MV policy 25,497 0 Reference
MV-for-all policy 91,413 4223 discounted LYG 15.6 USD/LYG
MV-for-all policy 91,413 160 deaths averted 412 USD/death averted
Note: LYG – life years gained.
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with the results obtained in traditional cost-effectiveness
studies.
Implications
The WHO recommends 95% MV coverage to control
measles infections [2]. Even though only the targeted
effects of MV are taken into account, scaling up
routine vaccinations in accordance with the goals of
the Global Immunization Vision and Strategy (GIVS)
[33] was estimated to be very cost-effective: requiring
additional USD 0.5 per capita to realize, routine vac-
cination scale-up is considered one of the cheapest
child health interventions in Africa [34].
Scale-up of vaccinations, however, stands in con-
trast to the strict wastage targets imposed by the
EPI programme in Guinea-Bissau [14,35] to fulfil
the wastage targets made by GAVI and UNICEF
[35]. In general, there are two strategies to reduce
open vial vaccine wastage: reduce vial size or
increase vaccination session size [36]. In Guinea-
Bissau, the latter has been the strategy and the
restrictive MV policy is in part a result thereof.
Introducing one-dose MV vials as a strategy has
to our knowledge not been considered in Guinea-
Bissau. In a simulation study of measles vial size
from Niger, decreasing vial size from 10-dose to 1-
dose vials increased the total volume of vials, cold
chain and safe injection equipment, thereby increas-
ing the costs of vaccine administration and waste
disposal, which far outweighed the costs saved from
the decrease in wasted doses [37]. The cost of
single-dose vials was 0.77 USD in 2003 [22].
Hence, the price of vaccinating children using 10-
dose vials is lower if only 3 doses are used from
each 10-dose MV vial. In the present study, vacci-
nating more than one child per vial (or 88%
wastage) was cost-saving. Thus, the cheapest and
simplest way to increase MV coverage is to abolish
the restrictive MV policy and open a MV vial for
every child irrespective of age and session size.
Conclusions
One of the major challenges in controlling measles is
to increase MV coverage. With this study, we propose
that one simple and cheap way of increasing coverage
is to remove restrictions imposed by wastage targets
and age limits. We have shown that in a setting with
biannual home visits, removing wastage targets and
the age limit could achieve a coverage of up to 97%,
which is in line with the recommendations of the
WHO to control measles [38]. Taking the low cost
of MV and the marked beneficial effects associated
with MV into consideration, we recommend that a
10-dose MV be reclassified as a ‘1+ dose vial’, which
is opened for a single child, irrespective of age, but
which can be extended to vaccinate up to 10 children.
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Paper context
Measles vaccination is a very cost-effective child health inter-
vention, aimed at reducing measles infections and deaths.
Taking non-specific effects of the measles vaccine into
account, we estimated the incremental cost-effectiveness of
providing measles vaccination for all children in Guinea-
Bissau. Abandoning strict measles vaccine wastage policies
was very cost-effective in Guinea-Bissau and potentially even
cost-saving. Policy makers should take non-specific effects of
vaccines into account when calculating cost-effectiveness.
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